Neuronoff hits first-in-human milestone for Injectrode neuromod

Injectrode placement over the course of treatment. [Image courtesy of Neuronoff]Neuronoff announced today that it completed the first-in-human clinical trial evaluating its flagship Injectrode neuromodulation product.

The Cleveland-based company designed Injectrode to treat chronic pain. The LIFE (lumbar Injectrode feasibility evaluation) trial evaluated Injectrode’s safety and effectiveness, meeting all goals, the company said. Injectrode placement comes through an 18-gauge needle (no incisions) under local analgesia at the level of the skin and subdermis. Doctors determine placement location using fluoroscopic visualization then confirm it with electrical test stimulation during placement.

According to a news release, 10 participants received Injectrodes (injectable electrodes) placed unilaterally or bilaterally near the dorsal rami innervation to the erector spinae and multifidus muscles in the lower back for less than 30 days. Peripheral nerve stimulatio…

Read more
  • 0